Table 5:

Results for Model (4) Using Data From ENGAGE (N = 159)

Parameter	Estimate	SE	95%CI: Lower Limit	95%CI: Upper Limit
Intercept	33.11**	0.50	32.13	34.08
Month 0 Treatment Readiness (TR0)	2.57**	0.31	1.97	3.18
Gender (Male=1; Female=−1)	0.93**	0.35	0.25	1.62
Gender * TR0	−0.51ϯ	0.30	−1.09	0.07
S1	−0.97**	0.38	−1.71	−0.22
S2	−0.30	0.49	−1.27	0.67
$S_2^2$	0.00	0.12	−0.23	0.22
S1×A1	−0.48*	0.24	−0.95	0.00
S2×A1	1.26**	0.49	0.30	2.22
S2×A2	0.29	0.23	−0.15	0.73
S2×A1×A2	0.19	0.23	−0.27	0.65
S22×A1	−0.31**	0.12	−0.54	−0.08
S22×A2	−0.05	0.06	−0.16	0.06
S22×A1×A2	−0.04	0.06	−0.15	0.08
Estimated Means at Month 1 / Month 2
Choice-Throughout $\left(1,1\right)$	35.38 / 33.94	0.49 / 0.62
Later-Choice $\left(-1,1\right)$	35.85 / 35.36	0.48 / 0.65
Estimated Means at Month 3 / Month 6
Choice-Throughout $\left(1,1\right)$	34.98 / 33.28	0.66 / 0.73
Later-Choice $\left(-1,1\right)$	34.19 / 34.12	0.71 / 0.77
Estimated Differences between Choice Throughout and Later Choice in Terms of Time-Specific Outcomes
Month 1	−0.48*	0.24	−0.95	0.00
Month 2	−1.43*	0.73	−2.85	0.00
Month 3	0.79	0.80	−0.78	2.35
Month 6	−0.84	0.93	−2.66	0.98
Estimated Area Under the Curve (AUC) at Stage 1 (Months 1– 2); Stage 2 (Months 2–6)
Choice-Throughout $\left(+1,+1\right)$	34.66, 141.62	0.51, 3.13
Later-Choice $\left(-1,+1\right)$	35.61, 133.03	0.52, 3.38
Estimated Overall AUCs (by month 6)
Choice-Throughout $\left(+1,+1\right)$	176.28	3.57
Later-Choice $\left(-1,+1\right)$	168.64	3.37
Estimated Differences between Choice Throughout and Later Choice in terms of AUCs
Stage 1	−0.95*	0.49	−1.90	0.00
Stage 2 (by month 6)	8.59ϯ	4.70	−0.61	17.79
Overall (by month 6)	7.64	4.71	−1.60	16.88
Estimated Delayed Effects in Terms of:
Time-specific outcomes by month 6	−0.59	0.88	−2.32	1.14
AUC by month 6	−9.54*	4.26	−18.70	−2.01

^ϯp≤0.10;

^*p≤0.05

^**p≤0.01

CI=95% Confidence Interval

SE=Standard Error